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Reflecting on the final report of the O’Neill Review on Antimicrobial Resistance 
To resolve the crisis of antimicrobial resistant infections and dearth of new treatments, the Review 
on Antimicrobial Resistance makes ten wide-ranging recommendations in their final report.1 
Implementation of the recommendations is to be achieved by increasing awareness, tackling supply 
of new treatments, preventing infections, using current treatments better, and reducing antibiotic 
use in agriculture and pollution of the environment. By 2050, they estimate the societal and financial 
cost of not tackling the crisis will be US$100 trillion. The Review reveal that, at roughly $30 billion, 
implementing all proposed recommendations is far cheaper than allowing the crisis to worsen until 
many infections are untreatable.  
The disciplines of microbiology and infectious diseases, and antimicrobial discovery, research and 
development have suffered from many years of underinvestment by the public and private sectors. 
Consequently, there is a lack of reward for these scientists and physicians; this is reflected by lower 
measures of esteem and salaries compared with other disciplines and so a shortage of expertise. The 
Review indicates that the crisis of antimicrobial resistance will not be tackled effectively without 
increasing the numbers of health-care professionals with specialist knowledge to provide leadership 
on the use of antimicrobials in people, and scientists to discover and research new treatments to 
feed into the commercial sector for development.  
A global public awareness campaign is recommended. This will inform everybody, irrespective of 
demographic group, of globally consistent core messages to reduce patient demand and 
antimicrobial use in animals. As it takes a long time to discover, research, develop, and manufacture 
new drugs, the Review recommends making better use of existing treatments. This is an approach 
taken by the British Society for Antimicrobial Chemotherapy (BSAC) Antibiotic Action initiative,2 
which has networked with like-minded groups (eg, ReAct, CDDEP, APUA, and WAAAR). Recently, 
BSAC, in collaboration with the University of Dundee and FutureLearn, launched a so-called Massive 
Open Online Course on antimicrobial stewardship for health-care professionals across the world.3  
Prevention of infection is far better than cure; especially as new antimicrobials to treat all drug-
resistant infections could be decades away. A major factor in the development and spread of 
antimicrobial resistance is that globally many people live in unhygienic conditions without access to 
clean water. The Review recognised that good sanitation is crucial to preventing the spread of 
infection. They recommend monitoring the levels of antimicrobial-resistant microbes and that 
infection prevention and control is embedded globally in all health-care and agricultural systems. 
Furthermore, consumption of antimicrobials should be measured in people and animals. Antibiotics 
are also frequently released into the environment, including into rivers near manufacturers’ 
production facilities. Therefore, introduction of a target for the maximum amount of antimicrobials 
allowable in wastewater is recommended and that this is monitored via a regulatory framework.  
To further prevent infection and reduce antimicrobial use, the Review recommends increased use of 
existing vaccines in people and in animals particularly in low-income countries and research to 
develop, manufacture, and provide new ones. Other ways to treat or prevent infections including 
alternative treatments such as phage therapy or repurposing of other therapeutics warrant close 
scrutiny and research.4  
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New antimicrobials will still be needed because this is a form of medicine acceptable to patients and 
health-care professionals. However, compounds that were readily druggable have already been 
made into medications. Finding inhibitors of drug-resistant pathogens, particularly Gram-negative 
bacteria and Mycobacterium tuberculosis, is technically difficult and it is hard to translate inhibitors 
from the laboratory into a new treatment. Since 2000, most new discoveries and much preclinical 
research has been done in academia or Small Medium Enterprises but the lack of return of 
investment is a barrier to Big Pharma developing some of these inhibitors. Therefore, working in 
collaboration with the IMI-funded project DRIVE-AB, the Review has suggested that the market be 
stimulated to develop and sell new antimicrobials by providing a reward system to those producing 
new treatments that will be of huge benefit to society even if they are not used. They also suggest 
the parallel development of new diagnostic tests to quickly and accurately diagnose infections at the 
time of treatment.  
There has been a dearth of funding for antimicrobial-resistance research including for new 
treatments5,6 and public funding agencies did not fill the void when pharmaceutical companies 
started merging and divesting themselves of this area of activity. Therefore, the Review 
recommends that a Global Innovation Fund for antimicrobial resistance should be established to pay 
for early stage research; the UK Prime Minister and the President of China have already indicated 
their intention to jointly contribute £100 million. Most antimicrobial-resistance researchers are in 
high-income countries and the continual depletion of expertise will need to be stemmed so that they 
can share their expertise and provide training to individuals in low-income and medium-income 
countries.  
The Review observed that when there are perceived global infection crises—eg, Ebola virus 
disease—governments and public funding agencies quickly respond and provide billions of dollars 
(including for research). The antimicrobial-resistance crisis has arisen stealthily; therefore, increased 
funding has not been seen as necessary. However, the findings of the Review team make it 
eminently clear that globally the antimicrobial-resistance crisis overshadows recent threats by many 
orders of magnitude. 
The ability of the Review to interact and influence the World Health Assembly, the G20, and the 
United Nations to act on their recommendations cannot be underestimated. If all the 
recommendations are fully implemented and antimicrobial resistance is overcome, this will be one 
of the most significant achievements of the 21st century, will save countless weeks and months of 
lost productivity, and will avert unnecessary deaths due to difficult and untreatable infections. 
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[Margin links] 
For more on the British Society for Antimicrobial Chemotherapy Antibiotic Action initiative see 
http://antibiotic-action.com/  
For more on Action on Antibiotic Resistance see http://www.reactgroup.org/  
For more on the Alliance for the Prudent Use of Antibiotics see 
http://emerald.tufts.edu/med/apua/ 
For more on the World Alliance Against Antibiotic Resistance see 
http://www.ac2bmr.fr/index.php/en/  
For more on The Centre for Disease Dynamics, Economics and Policy see http://www.cddep.org/ 
For more on Driving reinvestment in Research & Development for antibiotics and advocating their 
responsible use see http://drive-ab.eu/ 
 
